PO110 ASSESSMENT OF EARLY PROGRESSION RISK FOR PATIENT WITH ESR1 MUTATIONS AND HORMONE RECEPTOR POSITIVE (HR+)/HER2-NEGATIVE METASTATIC BREAST CANCER (MBC)

作者
Tetiana Tarasenko,Liubov A. Syvak,Olena Martyniuk,Maryna Bondar
出处
期刊:The Breast [Elsevier BV]
卷期号:71: S52-S53
标识
DOI:10.1016/s0960-9776(23)00674-4
摘要

Trastuzumab, other innovative drugs became available, including lapatinib.Therefore, the Dushanbe City Counseling Center, together with the Republican Cancer Institute and the NGO Avesta, recruited the humanitarian drug lapatinib to treat women with metastatic cancer and HER-positive status.A total of 56 women with advanced and metastatic cancer were selected.The primary diagnosis of disseminated breast cancer was in 19 women (34%), and metastatic relapse was in 37 women(66%).CNS metastases were found in 11 women, and liver metastases were found in 26 women.Eleven women (19%) received anthracycline therapy before lapatinib administration.The women were separated by age: 31 women were in the 45-60-year group, and 25 women were in the 60-75 year group.All women received positive IHC and FISH tests to confirm HER-positive status.Results of lapatinib treatment and the drug's effect on metastatic cancer: Women were treated with lapatinib for 24 weeks at a dose of 1,250 mg orally once daily on Days 1-21 continuously in combination with capecitabine.After treatment evaluation, brain metastases had not progressed in 7(12%) women, and two women experienced a decrease in the size of their metastases.8(14%) women with liver metastases had no progression of liver metastases, and 23 women had progression and growth of metastases.Impact of humanitarian delivery of lapatinib on the cancer care system: 1.The Cancer Institute opened a lab to diagnose HER2 status. 2. The Oncology Institute started working on a protocol for the treatment of women with advanced and metastatic cancer, which is vital for a country with limited resources.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
水长聿完成签到,获得积分10
刚刚
脑洞疼的应助被小金鱼166采纳,获得30
刚刚
风吹麦浪发布了新的文献求助10
1秒前
今后的应助被donkey采纳,获得10
1秒前
风吹麦浪发布了新的文献求助10
1秒前
1秒前
风吹麦浪发布了新的文献求助10
2秒前
2秒前
希望天下0贩的0的应助被lsq108采纳,获得10
2秒前
电池小白完成签到,获得积分10
2秒前
2秒前
人族首领完成签到,获得积分10
3秒前
浮华乱世完成签到,获得积分10
3秒前
小马甲的应助被12采纳,获得10
5秒前
风吹麦浪发布了新的文献求助10
5秒前
风吹麦浪发布了新的文献求助10
5秒前
5秒前
风吹麦浪发布了新的文献求助10
6秒前
6秒前
科目三的应助被2025采纳,获得10
7秒前
晚上吃什么完成签到 ,获得积分10
8秒前
SciGPT的应助被Rencal采纳,获得10
9秒前
风吹麦浪发布了新的文献求助10
9秒前
柑橘乌云发布了新的文献求助10
9秒前
风吹麦浪发布了新的文献求助10
9秒前
风吹麦浪发布了新的文献求助30
10秒前
科研通AI6.2的应助被LeeNeaul采纳,获得10
10秒前
10秒前
洛莫完成签到,获得积分10
11秒前
开朗钢铁侠完成签到 ,获得积分10
12秒前
13秒前
广州队完成签到,获得积分10
13秒前
淡然丹妗发布了新的文献求助10
14秒前
15秒前
英姑的应助被lsq108采纳,获得10
15秒前
15秒前
666完成签到,获得积分20
16秒前
18秒前
monster发布了新的文献求助10
18秒前
paulmichael发布了新的文献求助10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185762
求助须知:如何正确求助?哪些是违规求助? 9574458
关于积分的说明 21836217
捐赠科研通 7783574
什么是DOI,文献DOI怎么找? 3434651
关于科研通互助平台的介绍 2559017
邀请新用户注册赠送积分活动 2481466